Lara Fruergaard Jorgensen, chief of Novo Nordisk, the Danish Drug Group, which overtook LVMH this year as Europe’s most valuable company is behind the obesity treatments Wegovy and Ozempic. The drug will be available for treatments for a disease affected by over 1bn people by 2030.

Its results about reduced risk of heart attacks  also is boon lot of people. Wegovy was first approved in the US in 2021. The sales of Wegovy reached $4.2 bn this year and $7.3 bn  next, Ozempic  designed for diabetes  but often prescribed for obesity  is predicted to hit  $13.3bn in 2023 and $16.5 bn in 2024.